Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/33014
Title: Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project.
Authors: 
Keywords: 
Mesh: 
Issue Date: Mar-2018
Citation: Reumatol Clin.;(14)2:90-96
Abstract: To date, between 17% and 35% of patients with rheumatoid arthritis (RA) do not respond as expected to the initial biological therapy. The objective of this project is to recognize and weigh the attributes of biologic DMARD (bDMARD) to identify the most appropriate for each case, in the first lines of treatment of RA (after inadequate response to at least one synthetic DMARD or previous bDMARD).
PMID: 28065486
URI: https://hdl.handle.net/20.500.12530/33014
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos
Hospitales > H. U. Infanta Sofía > Artículos
Hospitales > H. U. de Getafe > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.